Optellum, based in the TMC Innovation Institute, has entered into a partnership with Johnson & Johnson. Photo via Getty Images

Optellum, a startup whose technology helps doctors detect and treat lung cancer, has teamed up with one of the world's health care giants to broaden the software's reach.

On August 18, Optellum — whose U.S. headquarters is at Houston's TMC Innovation Institute — unveiled its new collaboration with the Lung Care Initiative at Johnson & Johnson, which racked up global sales of $82.6 billion last year. Optellum's key contribution to the partnership is its AI-powered software that aids medical professionals in detecting and treating patients with lung cancer.

With Optellum's AI-powered lung cancer diagnostics now being included in J&J's Lung Cancer Initiative, medical teams soon will enjoy access to an array of complementary technologies designed to improve diagnosis and treatment of early stage cancer. The Lung Cancer Initiative, launched in 2018 by J&J and Boston University, aims to prevent, detect, and cure lung cancer.

Lung cancer ranks as the world's most common type of cancer and leading cause of cancer deaths. About 1.8 million people around the world die from lung cancer each year. The current five-year survival rate is just 20 percent, primarily due to most patients being diagnosed after the disease has reached an advanced stage.

Optellum's Virtual Nodule Clinic software received clearance from the U.S. Food and Drug Administration (FDA) in March. Hospitals in the U.S. are rolling out the technology, with Asia-Pacific and European hospitals on track to eventually adopt the software.

The Optellum platform identifies and tracks at-risk patients, and assigns a "lung cancer prediction" score to lung nodules — small lesions, frequently detected in chest CT scans, that may or may not be cancerous.

"Optellum's vision is to redefine the early intervention of lung cancer by enabling every patient to be diagnosed and treated at the earliest possible stage, when the chances of cure are highest," the United Kingdom-based company says in a news release.

The startup — a 2019 graduate of the Texas Medical Center's accelerator — hopes to apply the technology to other lung diseases, such as chronic obstructive pulmonary disease (COPD).

Optellum recently was named one of the 101 best medical device startups in the United Kingdom. In June, the startup was among 38 AI projects chosen by the UK Department of Health and Social Care to participate in a roughly $50 million health care initiative.

Václav Potěšil, founder and CEO of Optellum, says the Johnson & Johnson collaboration represents a "significant milestone" for his company.

The J&J partnership "brings us one step closer to Optellum's vision of redefining early lung cancer treatment by helping every clinician in every hospital to make the right decisions and provide their patients the best chance to fight back," Potěšil says.

Of the 35 people employed by Optellum, three are based in the U.S. and the rest in the United Kingdom. The company's team also includes several part-time consultants, most of whom are based in the U.S. By the end of this year, Optellum plans to expand its U.S. team with several full-time hires, including a senior executive located in Houston.

Beginning next year in Houston, Optellum expects its technology to be available for patients in clinical settings.

For Potěšil, Optellum's mission is personal. He lost an aunt to lung cancer within a year of her Stage 4 diagnosis.

"I've seen firsthand how very healthy people can be killed, and it's still the most common and deadliest cancer worldwide," Potěšil is quoted as saying by the Texas Medical Center. "We are really focused on enabling cancer patients to be diagnosed at the earliest possible stage and be cured. It's not just the modeled data on the computer. It's addressing the right clinical problems to add value to doctors."

Houston can expect the new vaccine in the next week. WPA Pool / Getty Images

Here's when Houston can expect the Johnson & Johnson COVID-19 vaccine

coming soon

Texas can expect to receive the first 200,000 doses of the coveted Johnson & Johnson COVID-19 vaccine this week. The company announced that it has started the rollout process on March 1 — after the FDA approved its Emergency Use Authorization.

The Center for Disease Control gave the developer, Janssen Pharmaceutical, the final greenlight Sunday, February 28.

What does that mean for Houston? Mayor Sylvester Turner said the Houston Health Department is also anticipated to be on the list to receive Johnson & Johnson doses within the next seven days.

"That will be a game changer," Turner said at an event on February 28 afternoon. "There will be more vaccines available in a shorter period of time. We anticipate that we will probably get a shipment in sometime this week that will add to the Pfizer [doses] that we are using at NRG."

Turner said other clinics with the Houston Health Department have been administering the Moderna vaccine.

The Johnson & Johnson vaccine does have noticeable differences from the Pfizer and Moderna vaccines, experts said.

The MRNA vaccines each require two shots which are usually delivered weeks apart and stored in freezers. The Johnson & Johnson vaccine is a single shot that can be stored in a refrigerator for up to three months at 35 to 46 degrees.

However, Johnson & Johnson does not have as much of the COVID-19 vaccine produced as originally anticipated. ABC13 confirmed 3.9 million doses will be shipped out across the country this week. Johnson & Johnson announced roughly an additional 16 million doses by the end of the month.

"In the next few weeks, it won't have much of any impact because they only have at least three or four million doses available, and that's disappointing news," says Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine. "In the longer term, over the next few months, it's really important because we need a greater vaccine supply. We are not going to get there with the two MRNA vaccines. We need probably up to five different vaccines in order to vaccinate the American people."

Recently, there has been a decline in COVID-19 hospitalizations and COVID-19 cases reported statewide. As of Sunday, about 5,700 Texans are in the hospital due to COVID-19, which is half the number of hospitalization in the beginning of the month.

Infectious disease epidemiologist Dr. Catherine Troisi says it's important for people to not let their guard down and that people should get tested if they have been in a high-exposure situation, or if they have been in direct contact with someone who has tested positive.

"Get vaccinated, don't worry about what vaccine it is," Dr. Troisi notes. "It's true that unfortunately there are not as many doses right now of the Johnson & Johnson vaccine as we have hoped, but the company is saying that by the end of June, they will have a 100 million doses, and that's into 100 million people because you don't need two doses.

"So, we expect to have 600 million doses of the other two vaccines, that's 300 million people," she continues. "That should be enough for everyone who wants the vaccine to be able to get it. With one caveat and that is as of right now we do not have a vaccine for children under age 16. Those trials are going on, hopefully as we go throughout the year there will be a vaccine licensed to 12 year-olds and then maybe going down to 8 years or older."

For more details on the Johnson & Johnson vaccine rollout, visit the FDA's website.

---

This article originally ran on CultureMap. For more on this story, visit our news partner ABC13.

Tom Luby will run the Texas Medical Center's Innovation Institute. Courtesy of TMC

TMC names former JLABS leader as the director of the Innovation Institute

taking control

The Texas Medical Center didn't have to go very far to find its new Innovation Institute director. Tom Luby, who most recently served as the site head for Johnson & Johnson Innovation's JLABS @ TMC, has been hired for the position.

"I am very excited to begin the next chapter in my journey at TMC Innovation," Luby says in a release. "My time at JLABS @ TMC has shown me the tremendous opportunity there is to work with a host of talented people and companies here in Houston. Now, I'm ready to expand my role and help take TMC Innovation as a collective unit to the next level."

Luby replaces Erik Halvorsen, who left abruptly in December. According to LinkedIn, Halvorsen is now the chief business and strategy officer for Houston-based FAR Biotech, for which he previously served on the board of directors. Lance Black, associate director at TMCx, served as the director in the interim for the past few months.

Prior to JLABS, Luby was in Boston at Johnson & Johnson and served as the new ventures lead. He has 14 years of research and design experience in the Boston area.

TMC as an organization has a lot up its sleeves, says President and CEO Bill McKeon in a release, and he trusts Luby to take the lead on innovation.

"With major developments in 2018, including the announcement of the forthcoming TMC3 translational research campus, Texas Medical Center is now on the fast track to becoming the third coast for life sciences, and TMC Innovation is a critical component in the ultimate realization of this goal," says McKeon. "Tom Luby is an outstanding individual, and his proven track record working with startups in Boston and within the walls of JLABS @ TMC will serve him well as he leads us through the next evolutionary phase of the TMC Innovation Institute."

Luby will oversee the med center's accelerator program, TMCx, which is currently in the midst of its eighth cohort.

Houston has just been named an emerging life sciences hub by CBRE. The recognition took job growth and lab space into consideration for the ranking.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston biotech company expands leadership team

growing biz

An innovative Houston startup that's working with energy companies to decarbonize their operations has made changes to its C-suite.

Tara Karimi, who co-founded Cemvita with her brother Moji, has transition to the company's chief science officer. Liz Dennett has been hired to Karimi's previous role of CTO. The changes enable Karimi to focus on leading Cemvita's scientific research and development efforts as well as participating in driving innovation within the biotech industry as a whole, according to the company's press release.

"I'm excited to take on the role of chief science officer at Cemvita and what it represents for our company's growth," says Karimi in the release. "As chief science officer, I look forward to shaping policy and driving the conversation around the role of biotechnology in the energy transition."

As CTO, Dennett will lead the development of Cemvita's unique biotech products that tap into microbes to decarbonize operations on energy plants. Most recently, Dennett was vice president of data architecture and data engineering at Wood Mackenzie. She previously worked in tech and sustainability-focused roles at Hess Corp., Biota Technology, and Amazon Web Services.

“Working with biological systems presents a unique challenge but also a unique opportunity," says Dennett in the release. "It’s uniquely difficult to go from benchtop to in-situ reactors or oil wells with microbes and to achieve the kind of incredible results that we’re seeing in the lab. You need to build teams with deep specializations in chemistry, biology, energy systems, and geology.”

Dennett, who has her PhD and Master's from the University of Wisconsin-Madison and has served on Cemvita's advisory board for about a year, will report to CEO Moji Karimi directly.

“I know that Tara and Liz are going to make history at Cemvita,” says Moji Karimi in the release. “With 15 years of experience using data-driven approaches to solve pressing energy challenges, Liz brings to bear the kind of creativity and expertise that can quickly and meaningfully advance Cemvita’s impact on the Energy Transition.”

Houston medical device startup names new CEO

now at the helm

Houston-based medical device company Saranas has tapped a veteran of the healthcare industry as its new CEO.

Mike MacKinnon most recently was president and partner at Madison Ventures +, a private equity firm based in Greenwood Village, Colorado. The firm invests in companies in healthcare, real estate, finance, and other sectors.

Before joining Madison Ventures +, MacKinnon was CEO of Zidan Medical, a startup focused on treatment of airway lesions in patients with early stage lung cancer. He served in that role from 2019 to 2023.

Earlier, he was CEO of ROX Medical, a medical device company specializing in minimally invasive vascular therapy for patients with uncontrolled high blood pressure. He held that role from 2018 to 2019. He previously worked at Philips North America, Volcano, AtheroMed, Hansen Medical, Access Closure, and FoxHollow Technologies.

In a news release, Dan Wolterman, chairman of Saranas’ board and former president and CEO of Memorial Hermann Health System, calls MacKinnon “an accomplished executive with an impressive record of bringing disruptive technology to market, guiding strategy, and driving significant growth.”

Now president and CEO of Nashua, New Hampshire-based medical device company Conformal Medical, James Reinstein was president and CEO of Saranas from 2020 to 2022. Prior to Reinstein, Zaffer Syed held that position from 2017 to 2020. He's still an adviser for the company and recently announced his role as entrepreneur in residence at the Texas Medical Center.

Saranas is working on commercializing its Early Bird Bleed Monitoring System, touted as the first and only system FDA-approved bleeding detection system for procedures involving blood vessels. It is designed to detect bleeds early, enabling physicians to reduce medical risks and potentially avoid costly medical problems.

“Bleeding remains a common issue during and after endovascular procedures and can result in life-threatening complications,” says MacKinnon.

Since being founded in 2013, Saranas has treated over 1,200 patients with its device and has received $29.2 million in funding, according to Crunchbase. This includes a $12.8 million Series B round that Saranas got in 2021 from Chicago-based Baird Capital and Austin-based S3 Ventures.

The Early Bird device was developed at Houston’s Texas Heart Institute. The FDA approved the device in 2019.

Houston expert: How to embrace cognitive diversity in the workplace

guest column

Everyone thinks and processes information in their own unique way. Cognitive diversity refers to these differing styles, perspectives, and problem-solving approaches among individuals in a group. Cognitive diversity, in today’s evolving workplace, is recognized as a valuable asset. Teams that are cognitively diverse can enhance their innovation, creativity and overall performance. The challenge comes with group dynamics when there may be communication barriers, conflicts and biases.

Effective strategies to consider for managing cognitive diversity in the workplace are as follows.

Communicate and take action

Business leaders who recognize and embrace the value of diverse perspectives and cognitive styles are better able to manage any challenges that may arise within the organization. Leaders and managers should communicate the importance of cognitive diversity to their team and encourage employees to share their unique viewpoints and approaches. This also means managers should be aware of their own biases and avoid making assumptions about people in order to create a more inclusive environment.

When a company uses hiring practices that embrace cognitive diversity, brings forth varying perspectives and ways of problem solving. Identifying those who may think differently than others or who may challenge the status quo is many times identifying those who will become the company’s best innovators. Embracing a diverse group of thinkers will help foster a culture of inclusivity, open-mindedness, and innovation.

Encourage collaboration

Collaboration is key to the success of any team. When working together, different cognitive styles can complement each other’s strengths and compensate for any weaknesses. Studies show cognitive diversity within groups can accelerate learning and performance when faced with challenges. In order to get through some of businesses’ most complex situations, there needs to be different perspectives and viewpoints.

For the most innovative thoughts to be heard, people must have the space to raise their hand and speak up, but also, people must actively listen to what the person has to say. Managers should work to create opportunities for collaboration, whether it is building cross-functional teams or other group projects and encourage employees to openly communicate and give feedback to improve the outcome.

Provide training and development

Training and development opportunities focused on cognitive diversity can help employees understand their own communication styles and the communication styles of others. By educating and applying, taking action steps after training will help reduce biases and misunderstandings. Additionally, these trainings can increase empathy, which does not come natural for some, and respect among team members.

Businesses should also evaluate their current company training programs to make certain they are inclusive of different learning styles, such as using infographics for visual learners or having hands-on demonstrations. Another consideration is to incorporate self-paced learning into training and development plans. No matter the type of training, solicit feedback, and take it under consideration to continuously improve how teams can develop their skills. Feedback that is thoughtfully considered and implemented leads to more engaged employees overall.

Manage conflicts

Conflicts are inevitable; however, organizations should set clear expectations and policies for performance and behavior. Unfortunately, conflict can be exacerbated in a diverse environment. Managers should be primed with knowledge on how to resolve conflicts and help facilitate constructive conversations among both parties. Also, managers should know when to reach out for help from their supervisor or human resources.

For business leaders to successfully manage cognitive diversity in the workplace, they must intentionally work to develop a culture that embraces the differences in others. Savvy business leaders will enlist the help of their HR team or outside council, such as a professional employer organization, to ensure their strategies and policies for managing a cognitively diverse workplace are inclusive.

Most importantly, when the company culture embodies a diverse, equitable, and inclusive workplace, the employees tend to have the same values, especially when the expectations are clearly set. As a result, the business will become a more innovative and engaging environment where employees know how to leverage their own strengths and the strengths of others, no matter their cognitive style.

------

Fernanda Anzek is managing director of HR services with Insperity, a Houston-based provider of human resources and business performance solutions.